Answer
Farydak (panobinostat) is predicted from animal findings to carry a high risk of foetal death and developmental skeletal abnormalities; there are no clinical pregnancy studies, and use during pregnancy should occur only if expected benefits outweigh potential foetal risks.
Sources for this answer
- Farydak 10mg hard capsulespharmaand GmbH · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 3Document updated
Sources checked